Wisevoter
World

Researchers Identified New Melanoma Metastasis Pathway

A study uncovered an epigenetic mechanism involving EZH2 that regulates tumor microenvironment remodeling.

Updated on Sept. 19, 2026 in Cancer

Macro photograph of intricate blue and white microscopic fibers and crystalline patterns, illustrating biological cellular architecture.
Researchers have identified a molecular axis, the EZH2/TRIM28 pathway, that facilitates melanoma metastasis by regulating heparan sulfate enzyme expression. AI Illustration. Upload story photo >

Scientists have identified a non-canonical EZH2/TRIM28 axis that influences heparan sulfate remodeling in melanoma cells. This epigenetic pathway promotes metastasis by modulating specific enzyme expression.

Why it matters

Understanding these epigenetic programs is critical because they drive melanoma progression by remodeling the tumor microenvironment. Targeting these enzymes may offer a way to limit the spread of cancer.

CRISPR-mediated loss of EZH2 modulates the expression of SULF1 and SULF2 enzymes within melanoma cells. This process regulates heparan sulfate levels and promotes tumor migration.

The players

EZH2

This protein functions as a histone methyltransferase and is a central component of the Polycomb Repressive Complex.

TRIM28

This transcriptional intermediary factor acts as a corepressor and plays a vital role in epigenetic gene regulation.

The details

EZH2 promotes the enzyme SULF1 through a methyltransferase-independent interaction with TRIM28, while simultaneously repressing SULF2 through canonical PRC2 activity. Depleting SULF1 significantly impairs the ability of melanoma cells to migrate, invade, and metastasize.

Timeline

  1. September 19, 2026: The findings were published in a peer-reviewed research article.

The Big Picture

This discovery aligns with the ongoing work within the Nature Portfolio Communications Biology epigenetic research program. The findings extend current understanding of tumor microenvironment dynamics by identifying heparan sulfate remodeling as a key factor in cancer progression.

While this study provides a new potential target for future drug development, it does not currently change existing cancer treatment protocols. Patients should continue following established medical advice and standard care plans provided by their oncology team.

The takeaway

The identification of the EZH2/TRIM28 axis highlights how epigenetic regulation fundamentally alters tumor behavior. Future therapies may eventually leverage these findings to slow or prevent cancer metastasis.

Further reading

For more on the current state of oncology research, visit the Cancer section.

More information

View the complete peer-reviewed research article for full methodology and results.

Source note: This article includes information reported by Nature.